



Development of Vaccines against Zika Virus

Guest Editors:

Prof. Kar Muthumani

Prof. Dr. David A. Schwartz

Dr. Gary Kobinger

Deadline for manuscript
submissions:
closed (31 August 2018)

Message from the Guest Editors

Zika virus (ZIKV) is a neurotropic, mosquito-transmitted flavivirus, which recently, and alarmingly, has been demonstrated to be transmitted by sexual and transplacental routes. Of relevance is the transplacental route of infection because of its association with the development of microcephaly and other severe birth defects in babies born to ZIKV infected mothers. Currently, there are no approved vaccines or therapies to combat ZIKV infection. Immune-based therapies have historically been successful in controlling a number of viral infections. Therefore, development of new vaccines and therapies that can confer immunity and/or treat clinical symptoms of ZIKV is greatly desired.

I hope that you will agree to share your expertise in this area by writing a review article for our Special Issue. The journal will follow up with instructions and other logistics for your review.

Dr. Kar Muthumani
Guest Editor

Keywords: Zika virus; Flaviviruses; Vaccines; Animal models; Immune responses





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com